NCT07319975Not yet recruiting
Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity
Comparison of the Effects of Semaglutide and Tirzepatide Treatments in Combination With Exercise in Obesity Management
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
Obesity is a growing global health problem that affects people of all ages. It can lead to serious health issues such as cardiovascular disease, insulin resistance, inflammation, and reduced physical function. New medications, including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP agonists like tirzepatide, have been shown to help people lose significant weight. However, some of this rapid weight loss may come from a reduction in muscle mass rather than fat. Losing muscle can lower physical performance, impair metabolic health, and increase the risk of developing sarcopenic obesity. This study aims to compare the effects of pharmacological treatment alone with a combined treatment program that includes both medication and exercise in individuals with obesity. The primary objective is to evaluate how these two approaches influence body composition. The secondary objective is to examine the effects of pharmacological treatment versus combined treatment on cardiometabolic markers, peripheral muscle strength, functional capacity, respiratory function, respiratory muscle performance, and physical activity levels. The study seeks to determine whether adding structured exercise to medication can provide additional health benefits beyond weight loss.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 7 Dec 2025
- Start date
- 29 Dec 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Istanbul Galata University
- Diseases
- Obesity
- NCT number
- NCT07319975
What you commit to
- Study type: Interventional
- Planned participants: 48
- From 29 Dec 2025 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals with concomitant chronic respiratory disease
- Individuals who have had endoscopic intervention and/or bariatric surgery within the last year
Other illness
- Uncontrolled arrhythmia, hypertension, heart failure, diabetes, and unstable angina pectoris
- Cooperation impairment, orthopedic, and neurological problems that may interfere with evaluation and treatment
- Individuals with a history of lower extremity injury or surgery in the last six months
- Diagnosed with diabetes and complications such as nephropathy, retinopathy, and neuropathy
- Individuals with acute infections
- Individuals with a history of spontaneous or trauma-related pneumothorax
Other
- Individuals with a BMI greater than 40 kg/m2 according to the WHO classification
- Individuals with a Charlson comorbidity index score of 3 or higher
- Individuals with middle ear pathologies (such as tympanic membrane rupture, otitis media)
- Smokers
- Pregnancy
- Individuals with a STOP-bang score of 3 or higher
- Individuals on a structured diet program for weight loss during the study period
Who the study is looking for
- Those between the ages of 25 and 60 years
- Those with a body mass index (BMI) between 30 and 40 kg/m2 according to the World Health Organization (WHO) classification
- Individuals who volunteered to participate in the study
Age in the registry: 25 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Biruni University Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.